What makes tumors multidrug resistant?

Cell Cycle

Volumn 6, Issue 22, 2007, Pages 2782-2787

  Borst, Piet ^a   Jonkers, Jos ^a   Rottenberg, Sven ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Apoptosis; Breast cancer; Cisplatin; Docetaxel; Doxorubicin; Drug transporters; Multidrug resistance; P glycoprotein; Senescence

Indexed keywords

BRCA1 PROTEIN; CARRIER PROTEIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; PROTEIN P53;

APOPTOSIS; BREAST TUMOR; CANCER RELAPSE; CELL AGING; DRUG TOLERANCE; EPITHELIUM TUMOR; GENE DELETION; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW; TRANSGENIC MOUSE; TUMOR RESISTANCE; UPREGULATION;

ANIMALIA; MUS;

EID: 37249061592     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6.22.4936     Document Type: Review

References (47)

1. Jonkers J, Berns A. Animal models of cancer. In: Knowles M, Selby P, eds. Introduction to the Cellular and Molecular Biology of Cancer. Oxford University, 2005:317-36.
2. Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer 2007, (in press).
3. Rottenberg S, Nygren AOH, Pajic M, Van Leeuwen FWB, Van der Heijden I, Van de Wetering K, Liu X, de Visser KE, Gilhuijs KG, Van Tellingen O, Schouten JP, Jonkers J. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci USA 2007; 104:12117-22.
4. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455:152-62.
5. Borst P, Oude Elferink R. Mammalian ABC transporters in health and disease. In: Richardson CC, Kornberg R, Raetz CHR, Thorstensen K, eds. Ann Rev Biochem. California: Science, 2002:537-92.
6. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002; 2:48-58.
7. Sarkadi B, Homolya L, Szakacs G, Varadi A. Human multidrug resistance ABCB and ABCG transporters: Participation in a chemoimmunity defense system. Physiol Rev 2006; 86:1179-236.
8. Lowe SW, Bodis S, McClatchey A, Remington L, Earl Ruley H, Fisher DE, Housman DE, Jacks T. p53 Status and the efficacy of cancer therapy in vivo. Science 1994; 266:807-10.
9. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002; 109:335-46.
10. Schmitt CA, Lowe SW. Apoptosis is critical for drug response in vivo. Drug Resist Updates 2001; 4:132-4.
11. Schmitt CA, Wallace-Brodeur RR, Rosenthal CT, McCurrach ME, Lowe SW. DNA damage responses and chemosensitivity in the E mu-myc mouse lymphoma model. Cold Spring Harb Symp Quant Biol 2000; 65:499-510.
12. Schmitt CA, Rosenthal CT, Lowe SW. Genetic analysis of chemoresistance in primary murine lymphomas. Nature Med 2000; 6:1029-35.
13. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes and Dev 1999; 13:2670-7.
14. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002; 108:153-64.
15. Schmitt CA. Senescence, apoptosis and therapy-cutting the lifelines of cancer. Nat Rev Cancer 2003; 3:286-95.
16. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999; 59:1391-9.
17. Borst P, Borst J, Smets LA. Does resistance to apoptosis affect clinical response to antitumor drugs? Drug Resist Updat 2001; 4:129-31.
18. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005; 5:231-7.
19. Brown JM, Wilson G. Apoptosis genes and resistance to cancer therapy: What does the experimental and clinical data tell us? Cancer Biol Ther 2003; 2:477-90.
20. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006; 66:9339-44.
21. Clarke MF, Fuller M. Stem cells and cancer: Two faces of eve. Cell 2006; 124:1111-5.
22. Wicha MS, Liu S, Dontu G. Cancer stem cells: An old idea-a paradigm shift. Cancer Res 2006; 66:1883-90.
23. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006; 355:1253-61.
24. Dean M, Fojo T, Bates S. Tumor stem cells and drug resistance. Nat Rev Cancer 2005; 5:275-84.
25. Liu X, Holstege H, van der Gulden H, Treur-Mulder M, Zevenhoven J, Velds A, Kerkhoven RM, Van Vliet MH, Wessels LFA, Peterse JL, Berns A, Jonkers J. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with pathologic and molecular features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci USA 2007; 104:12111-6.
26. Fox E, Bates SE. Tariquidar (XR9576): A P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther 2007; 7:447-59.
27. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74:957-67.
28. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318:533-8.
29. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002; 1:289-98.
30. Wendel HG, de Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428:332-7.
31. Cory S, Vau DL, Strasser A, Harris AW, Adams JM. Insights from Bcl-2 and Myc: Malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res 1999; 59:1685s-92s.
32. Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updates 2001; 4:303-13.
33. Roninson IB. Tumor senescence as a determinant of drug response in vivo. Drug Resist Updat 2002; 5:204-8.
34. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI, Eaves CJ. Purification and unique properties of mammary epithelial stem cells. Nature 2006; 439:993-7.
35. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE. Generation of a functional mammary gland from a single stem cell. Nature 2006; 439:84-8.
36. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293:876-80.
37. Assaraf YG. Molecular basis of antifolate resistance. Cancer Metastasis Rev 2007; 26:153-81.
38. Sirotnak FM, Moccio DM, Kelleher LE, Goutas LJ. Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate- resistant L1210 clonal cell lines derived in vivo. Cancer Res 1981; 41:4447-52.
39. O'Driscoll L, Clynes M. Biomarkers and multiple drug resistance in breast cancer. Curr Cancer Drug Targets 2006; 6:365-84.
40. Schinkel AH, Mayer U, Wagenaar E, Mol CAAM, Van Deemter L, Smit JJM, Van der Valk MA, Voordouw AC, Spits H, Van Tellingen O, Zijlmans JMJM, Fibbe WE, Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997; 94:4028-33.
41. Schinkel AH, Borst P. Multidrug resistance mediated by P-glycoproteins. [Review]. Seminars in Cancer Biol 1991; 2:213-26.
42. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, Richardson A, Weinberg RA. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA 2004; 101:4966-71.
43. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21.
44. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434:913-7.
45. Lord CJ, Garrett MD, Ashworth A. Targeting the double-strand DNA break repair pathway as a therapeutic strategy. Clin Cancer Res 2006; 12:4463-8.
46. Derksen PW, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, van Beijnum JR, Griffioen AW, Vink J, Krimpenfort P, Peterse JL, Cardiff RD, Berns A, Jonkers J. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006; 10:437-49.
47. Stride BD, Grant CE, Loe DW, Hipfner DR, Cole SPC, Deeley RG. Pharmacological characterization of the murine and human orthologs of multidrug resistance protein in transfected human embryonic kidney cells. Mol Pharmacol 1997; 52:344-53.